Sim Kang, Chan Yiong Huak, Chua Thiam Hee, Mahendran Rathi, Chong Siow Ann, McGorry Patrick
Department of Adult Psychiatry, Woodbridge Hospital/ Institute of Mental Health, and Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Schizophr Res. 2006 Dec;88(1-3):82-9. doi: 10.1016/j.schres.2006.07.004. Epub 2006 Aug 14.
This prospective study sought to determine the clinical impact of physical comorbidity on patients with first episode schizophrenia (FES) and we tested the hypothesis that patients with physical comorbidity were associated with poorer clinical and functional outcomes. The severity of psychopathology, insight, social/occupational functioning and quality of life were evaluated using Positive And Negative Syndrome Scale (PANSS), Scale to assess Unawareness of Mental Disorder, Global Assessment of Functioning Scale (GAF), and World Health Organisation Quality of Life-Bref Scale (WHOQOL-Bref) respectively at baseline and at 6, 12, 18 and 24 months. Out of 142 patients, physical comorbidity was present in 21.8% (n=31) of the patients, and they were mainly related to the cardiovascular, respiratory and endocrine systems. Compared to baseline measurements, patients with physical comorbidity had greater awareness into the consequences of their psychiatric illness at 12 months, the need for treatment at 12 and 18 months, and better improvement of PANSS total and general psychopathology subscale scores at 24 months. FES patients with physical comorbidity also had less reduction in their WHOQOL-Bref scores in the physical health domain at 12 and 18 months and greater increase in the GAF scores at 18 and 24 months, indicating better subjective rating of quality of life and objective measure of their global functioning prospectively. Clinicians need to be aware of the substantial rates of physical comorbidity in FES patients which may not be necessarily associated with worse longitudinal outcomes and the findings should encourage even greater efforts at early identification and management of these physical conditions.
这项前瞻性研究旨在确定躯体共病对首发精神分裂症(FES)患者的临床影响,并检验了以下假设:患有躯体共病的患者临床和功能结局较差。分别在基线以及第6、12、18和24个月时,使用阳性和阴性症状量表(PANSS)、精神障碍自知力评定量表、总体功能评定量表(GAF)以及世界卫生组织生活质量简表(WHOQOL-Bref)评估精神病理学严重程度、自知力、社会/职业功能和生活质量。在142例患者中,21.8%(n = 31)的患者存在躯体共病,主要涉及心血管、呼吸和内分泌系统。与基线测量相比,患有躯体共病的患者在12个月时对其精神疾病后果的认识更强,在12和18个月时对治疗的需求更高,并且在24个月时PANSS总分和一般精神病理学分量表得分改善更好。患有躯体共病的FES患者在12和18个月时WHOQOL-Bref量表身体健康领域得分下降也较少,在18和24个月时GAF得分升高更多,这表明前瞻性地他们的生活质量主观评分更好,整体功能客观测量更佳。临床医生需要意识到FES患者中躯体共病的比例较高,这不一定与更差的纵向结局相关,这些发现应促使人们更加努力地早期识别和管理这些躯体疾病。